Finerenone improves outcomes in patients with mild-to-moderate kidney disease and diabetes

Finerenone reduces the risk of cardiovascular morbidity and mortality in patients with mild-to-moderate kidney disease and type 2 diabetes. Diabetic kidney disease develops in approximately 40% of patients with diabetes and is the leading cause of chronic kidney disease worldwide. Some patients progress to end-stage renal disease, but most die from cardiovascular diseases and infections before needing kidney replacement therapy.

from Latest Science News -- ScienceDaily https://ift.tt/38oaMto